| answer text |
<p>Prior to April 2013, information on the Cancer Drugs Fund was administered through
clinical panels based in each strategic health authority (SHA) and data on spend through
the Fund in each city was not collected. Information on spend by the North West SHA
and in England in 2010-11, 2011-12 and 2012-13 is shown in the following table:</p><p>
</p><p> </p><p> </p><table><tbody><tr><td><p> </p></td><td><p>Amount Spent (£000)</p><p>2010-11</p></td><td><p>Amount
Spent (£000)<br> 2011-12</p></td><td><p>Amount Spent (£000)<br> 2012-13</p></td></tr><tr><td><p>North
West SHA</p></td><td><p>7,400</p></td><td><p>10,015</p></td><td><p>29,272</p></td></tr><tr><td><p>England</p></td><td><p>38,254</p></td><td><p>108,327</p></td><td><p>175,334</p></td></tr></tbody></table><p>
</p><p><em>Source</em>: Information provided to the Department by SHAs</p><p> </p><p>
</p><p> </p><p>NHS England has had oversight of the Fund since April 2013 and does
not collect information at city level. In 2013-14, £63,368,429 was spent through the
Fund in the North of England region and total national expenditure in England, net
of any central rebates, was £230,539,005. Figures for 2014-15 are not currently available.</p><p>
</p>
|
|
